VISEN PHARMA-B (VISEN Pharmaceuticals) filed its monthly return for the period ended 31 August 2026, confirming a stable capital structure and compliance with Hong Kong Stock Exchange public-float requirements.

Authorised Capital • Authorised share count remained at 500.00 million ordinary shares with a par value of USD 0.0001, keeping total authorised capital unchanged at USD 50,000.

Issued and Treasury Shares • Outstanding shares (excluding treasury) stood at 113.75 million, while treasury shares were 173,500, leaving total issued shares at 113.93 million. • No shares were issued, cancelled, repurchased, or transferred during the month, resulting in zero change to both issued and treasury share balances.

Public Float • The company confirmed compliance with the Main Board’s minimum 25% public-float threshold as at 31 August 2026.

Equity Incentive Schemes • Post-IPO Share Award Scheme (adopted 16 November 2022) recorded no share issuances or treasury transfers in August. • The scheme’s current mandate allows up to 2.40 million shares to be issued upon vesting; historical grants comprise 435,000 shares in June 2025 and 514,068 shares in July 2026.

Regulatory Confirmation • The filing attests that any past share issuances have been duly authorised, funds received, and all Hong Kong listing rule conditions satisfied.

Overall, VISEN PHARMA-B maintained a static share capital base in August 2026 with sufficient public float, signalling capital stability ahead of future vesting events under its share award programme.